drugset / Trial / NCT06800092

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

NCT06800092

Phase 2/3 Not yet recruiting 30 enrolled The University of Texas Medical Branch, Galveston
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.

Timeline

Start
2027-06-15
Primary completion
2030-06-01
Completion
2030-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 50 mg

Indications